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Late liver metastasis of medullary thyroid cancer with low 
calcitonin levels — successfully cured by radiofrequency
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Abstract 
A 28-year-old female consulted in 1994 for a left thyroid nodule known for two years with documented progression. Left lobe resection 
was performed initially followed by total thyroidectomy without lymph node dissection in September 1994. Pathological examination 
concluded on unilateral 10 × 40 mm medullary thyroid carcinoma (MTC). RET mutation was negative. Basal and pentagastrin-stimulated 
CT levels had been normal from 1994 to 2008 when her CT level was found to be elevated at 33 ng/L and increased subsequently to 111 ng/L 
in 2010. In accordance with guidelines, cervical ultrasound was performed repeatedly with negative results. After discussion in a multi-
disciplinary meeting and with patient’s consent, an F-Dopa PET scan was proposed in disagreement with guidelines. This scan showed 
unique uptake in liver segment VI, which was confirmed by MRI. CT levels reached to 253 ng/L when she finally accepted treatment. In 
February 2013 we performed radiofrequency ablation of the lesion, which allowed normalisation of CT levels. This observation highlights 
the possibility of late recurrence of MTC. We could propose that for MTC patients with low-calcitonin levels-recurrences F-DOPA-PET/CT 
is a good diagnostic tool to use in case of repeatedly negative US neck studies. (Endokrynol Pol 2016; 67 (3): 326–329)
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Streszczenie 
Chora w wieku 28 lat zgłosiła się do lekarza w 1994 roku z powodu lewostronnego guzka tarczycy wykrytego 2 lata wcześniej, z potwier-
dzoną progresją. Wykonano resekcję lewego płata tarczycy. Totalną tyreoidektomię wykonano we wrześniu 1994 roku bez usunięcia 
węzłów chłonnych. W badaniu patomorfologicznych stwierdzono jednostronnego raka rdzeniastego tarczycy (MTC) o wymiarach 
10 × 40 mm. Wynik badania w kierunku mutacji RET był ujemny. Stężenia kalcytoniny (CT, calcitonin), podstawowe i po stymulacji pen-
tagastryną, były prawidłowe od 1994 roku. Do 2008 roku, kiedy stwierdzono podwyższone stężenie CT wynoszące 33 ng/l, a następnie 
jego dalszy wzrost do 111 ng/l w 2010 roku. Zgodnie z zaleceniami powtórnie wykonano badanie USG szyi, w którym nie stwierdzono 
nieprawidłowości. Po omówieniu przypadku na spotkaniu wielodyscyplinarnego zespołu i uzyskaniu zgody chorej przeprowadzono 
badanie F-Dopa PET (niezgodnie z zaleceniami), w którym wykazano pojedyncze ognisko wychwytu w segmencie VI wątroby, co zostało 
potwierdzone w badaniu MRI. Kiedy chora w końcu zaakceptowała leczenie, stężenia CT zwiększyły się do 253 ng/l. W lutym 2013 roku 
wykonano ablację zmiany prądem o częstotliwości radiowej, co pozwoliło uzyskać normalizację stężeń CT w 2015 r. Ta obserwacja zwraca 
uwagę na możliwość późnej wznowy. Autorzy sugerują, że u chorych z MTC z ponownie stwierdzonym niskim stężeniem kalcytoniny 
wybór F-DOPA-PET/CT jako metody diagnostycznej jest dobrym rozwiązaniem w przypadku powtórnych ujemnych wyników USG 
szyi. (Endokrynol Pol 2016; 67 (3): 326–329)
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Introduction
Medullary thyroid carcinoma (MTC) is a rare endocrine 
tumour that represents 5–10% of all thyroid cancers. 
MTC can be sporadic (75%), or inherited (25%) either 
as isolated disease or associated with other endocrine 
diseases such as pheochromocytoma or hyperparathy-
roidism [1]. The pathogenesis of MTC is tightly related 
to activating mutations of the RET (rearranged during 
transfection) proto-oncogene, which are germline in 
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most hereditary cases (in approximately 98% of cases) 
and somatic in many sporadic ones (in approximately 
45% of cases) [2]. Calcitonin (CT) is its specific marker 
with a high specificity and sensitivity; its level is related 
to tumour volume and prognosis [3]. 
Although the mortality due to MTC represents 
13.4 % of the mortality of all thyroid cancers [4], it has 
a relatively good prognosis with 10-year survival rates 
for patients with stages I, II, III, and IV of 100%, 93%, 
71%, and 21%, respectively [5]. MTC spreads rapidly 
to regional (cervical) lymph nodes. In the end stage of 
MTC, the usual sites of systemic metastasis are liver, 
lungs, and bones [6]. Thus, most MTC patients who 
have extensive regional lymph node metastases or sys-
temic disease are not cured by total thyroidectomy with 
bilateral neck lymph nodes dissection [5, 7]. In cases of 
persistent MTC or late recurrence radiotherapy and/or 
chemotherapy have low success rates and did not show 
evidence of lengthening the survival [1]. Debulking sur-
gery, loco regional approaches such as radiofrequency, 
have rare indications and consequently rare successes. 
Due to its high diagnostic accuracy, CT levels are 
used to follow MTC patients after initial treatment in 
order to detect persistent and recurrent disease. Moreo-
ver, CT levels are very useful in guiding workup. Recent 
American guidelines have been published indicating 
that in the case of post operative CT elevation less than 
150 ng/L it is recommended to look for recurrence in 
the neck or to keep a watchful attitude. We present 
a young patient with late MTC liver metastasis with 
a mild CT elevation of 111 ng/L but without cervical 
lymph node metastases, who was cured after unique 
radiofrequency treatment.
Case presentation 
A 28-year-old female, with no prior history, consulted 
in 1994 for a left thyroid nodule known for two years 
with documented progression. Left lobe resection was 
performed in September 1994. A suspected follicular 
carcinoma at frozen section motivated totalisation 
without lymph node dissection. Pathological examina-
tion was compatible with a unilateral 37 × 27 × 18 mm 
MTC (T2NxMx) with neither vascular invasion nor 
extra capsular extension. Immunostaining was positive 
for CT and CEA and negative for thyroglobulin. There 
was no C cell hyperplasia. A search for RET germline 
mutation in the patient’s peripheral blood lymphocytes 
was negative. 
Post-operative calcitonin levels were undetectable, 
while CEA levels were at 1.6 µg/L. Of note, no CT levels 
were available before surgery. Basal (not stimulated) CT 
levels (normal level < 10 ng/L) had been normal from 
September 1994 to June 2007 when her basal CT level 
was found to be elevated at 17 ng/L, and it increased 
subsequently to 111 ng/L in March 2010 (Fig. 1). Interest-
ingly, pentagastrin-stimulated CT levels were elevated 
in 2003 (46 ng/L; normal < 10 ng/L) but with normal 
basal CT levels. In accordance with guidelines [1] cer-
vical ultrasound was performed repeatedly between 
2007 and 2010 with negative results. After discussion 
in a multi-disciplinary meeting and with the patient’s 
consent, F-DOPA PET/CT scan was proposed as 
a diagnostic tool even though this was in disagreement 
with guidelines, especially recommendations 47 and 
48 in the recent guidelines [1]. F-DOPA-PET/CT scan 
showed unique uptake in liver segment VI with no 
cervical uptake (Fig. 2A). Hepatic ultrasound echogra-
phy did not localise the lesion, but magnetic resonance 
imaging confirmed the results of F-DOPA-PET/CT 
by showing a 7-mm lesion with moderate hyperin-
tensity on T2-weighted images, low signal intensity 
on T1-weighted images, and high signal intensity in 
diffusion sequences (Fig. 2B). No histologic analysis 
was done. Since the patient did not agree to receive 
local treatment, watchful waiting was done until CT 
levels increased to 253 ng/L (October 2011) — albeit 
a normal CEA level of 1.10 µg/L — when she finally 
Figure 1. Calcitonin levels evolution from 1994 to 2015
Rycina 1. Zmiany stężenia kalcytoniny w okresie od 1994 do 2015 roku
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accepted treatment. In February 2013, when she was 
47 years old, we performed radiofrequency ablation of 
the lesion, which allowed normalisation of CT levels for 
a 26 month-period (up to her last follow-up visit in 2015).
Discussion
This is certainly the first case of late unique liver me-
tastases detected by F-DOPA-PET/CT scan and suc-
cessfully treated by radiofrequency with such a long 
follow-up. This observation shows the limits of the 
recommended management of MTC patients in some 
cases. We could propose that for MTC patients with 
low-calcitonin levels-recurrences, F-DOPA-PET/CT is 
a good diagnostic tool to be used in the case of repeatedly 
negative US neck studies. 
Regional lymph node invasion is frequent 
and occurs early in MTC patients, as reported in 
Figure 2A. F-DOPA PET/CT imaging showing high uptake lesion in the liver; B. Abdominal MRI showing a hyper signal intensity 
lesion in the liver (diffusion-weighted imaging)
Rycina 2A. Badanie F-DOPA PET/CT pokazujące zmianę w wątrobie charakteryzującą się silnym wychwytem znacznika; B. Badanie 
MRI jamy brzusznej pokazujące zmianę o zwiększonej intensywności w wątrobie (obrazowanie dyfuzyjne)
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a 101 patients-series by Scollo et al. [8]. In sporadic MTC, 
lymph node metastases were observed in the central 
compartment and in the ipsilateral and contralateral 
jugulo-carotid chain in 50, 57, and 28% of cases, re-
spectively. In hereditary MTC, lymph node metastases 
were identified in the central compartment, and in the 
ipsilateral and contralateral jugulo-carotid chain in 45, 
36, 19% of cases, respectively. Liver metastases are less 
frequent and occur in 45% of patients with advanced 
MTC, and sometimes they are life-threatening. They 
are often multiple and disseminated throughout the 
hepatic parenchyma; and usually they are not acces-
sible to surgery, percutaneous ethanol, radiofrequency 
ablation, or chemoembolisation, nor do they respond 
well to systemic therapy [8]. Imaging techniques to 
detect persistent or recurrent MTC include cervical and 
abdominal US, neck and chest CT, three-phase contrast-
enhanced CT, contrast-enhanced MRI, bone scintigra-
phy, and FDG-PET/CT [9]. In advanced MTC diseases, 
the sensitivity of these tests in localising metastatic 
disease ranges between 50% and 80%. In a recent study 
on 41 patients, liver metastases were demonstrated in 
less than 50% by MRI (49%), CT (41%), US (41%), and 
FDG-PET/CT (27%) [9]. F-DOPA-PET/CT could have 
superior sensitivity and specificity [10].
This case report has several implications, albeit with 
some caveats.
In recent guidelines grade C recommendations 
47 and 48 indicate that patients with CT levels < 150 ng/L 
should have only physical examination and US of the 
neck and should be followed with physical examina-
tions, measurement of serum levels of CT and CEA, and 
US every six months, and only in the case of CT level 
> 150 ng/L should other imaging procedures be con-
sidered [1]. This is what had been done in our patient. 
However, repeated US studies of the neck showed no 
evidence of local disease, while the hepatic lesion was 
more than suspicious. The presence of unique liver 
metastasis with no regional lymph node and only a CT 
level of 111 ng/L is an exception. Imperial et al. reported 
a previous case but with higher CT levels [11].
Secondly, 18F-FDOPA PET/CT could help clinicians 
to find recurrence in patients with repeatedly negative 
cervical US studies [10]. The lesion-based detection rate 
by F-DOPA-PET/CT is around 70% and probably it 
could be of value in cases of mild elevation of CT levels 
where other imaging techniques have a low sensitivity. 
Thirdly, we cured our patient by radiofrequency 
with a long follow-up. That might be related to lesion 
dimensions because radiofrequency ablation is as-
sociated with better results in smaller lesions. Usually 
radiofrequency is used for cytoreduction in cases of 
disseminated diseases. Recurrences or deaths have been 
reported after use of this therapy [12]. 
Finally, this observation highlights the possibility of 
late recurrence of MTC (3.3% among a series of 453 pa-
tients) [13]. Thus, MTC-cured patients need long-term 
follow-up and annual CT level determination. 
In conclusion, future studies with sufficient num-
bers of patients are mandatory in order to determine 
whether patients who have MTC recurrence with CT 
< 150 ng/L gain some benefit by searching for liver 
metastases. The precise way in which F-DOPA-PET/CT 
can be used for the assessment of patients with MTC 
recurrence remains uncertain, but some data suggest 
that F-DOPA-PET/CT may be useful for risk stratifica-
tion and could indicate some local therapies.
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